Category Archives: Cancer Patients

Oncotarget Announces Its New Publication Platform On Pubmed and Reports on Recent Findings

Oncotarget is an intensive scientific journal that reports the findings of researches on various cases through Impact Journal. One recent scientific conclusion indicated that breast cancer cells are highly receptive to hormonal therapy. Oncotarget’s report detailed the drugs that practitioners can distribute for specific breast cancer types.

In the article, breast cancer cells were reported to contain a high reception to the hormones estrogen and progesterone. The most severe cancer type, TNBC, affects approximately 15 percent of all breast cancer victims. The severity of the case is aggravated by the cells’ inability to react positively to hormonal therapy. Their research was progressed farther by scientists at the Mayo Clinic, who sough to understand the operation of molecules so as to develop effective treatment. Oncotarget’s report states that Dr.Hawse of Mayo Clinic concluded that a cell cycle protein caused the non-receptive nature of cells in TNBC patients. The studies verified that cancer cells containing ERß have a high rate of redemption than the Era. Mayo Clinic plans to conduct farther analysis on animals to create an effectual treatment plan. Learn more about Oncotarget at

Oncotarget integrates the effort of highly revered scientists to output detailed and informative articles to its subscribers. It has recently began publishing with PubMed, and plans to increase its indexing. Since the conception of the contract, Oncotarget has publicized 7 volumes, and is set to launch the 8th, which is currently under procession by the National Library of Medicine.

Oncotarget has a strong resolve to meet the intellectual demands of the 21st century scientific community. They have secured a publishing platform with PubMed, ISI/Web of Science and EMBASE. Oncotarget has become the first scientific newsletter to have a space of PubMed, shortly after the launch of its online portal.


The journal’s team of editors and administrators state that their primary role is to enhance their reports to meet the quality demands of expert scientists. The office managing the legal affairs of the journal stated that they concentrate on providing scholar-based reading to subscribers with varied intrests in science. Oncotarget’s major audience consists of other scientists who consider the journal a trustworthy source to advance their research. Check the journal at SCImago Journal & Country Rank.

Source –

Clay Siegall Is The Driving Force For Helping Cancer Patients

Highly motivated to develop and expand cancer therapies, cancer research pioneer Clay Siegall has worked tirelessly to achieve advancements in inventive therapies for cancer patients.

Since co-founding Seattle Genetics in 1998, Siegall has almost twenty years in guiding the company to new scientific achievements. He is the current president, chief executive officer and chairman of the board of Seattle Genetics.

Siegall’s intense enthusiasm and passion have made it easier for him to lead the company to undertake new levels of research development.

Under his direction the company has built a diverse channel of antibody-based cancer therapies through its proprietary, industry leading technology.

Specifically, Seattle Genetics has built up its antibody-drug conjugate (ADC) technology that brings into play antibodies or other biologics produced by a single cell that transports highly active pharmaceutical ingredients to targeted cells.

ADCs, including the company’s first ADC product ADCETRIS, is now available in more than 60 countries.

Seattle Genetics has entered into many collaborations for its ADC technology including with companies such as GlaxoSmithKline, Pfizer, Genentech (Roche) and others.

Aside from his success in the new cancer therapy line of work, Siegall has proven his impact through his fundraising expertise.

For example, he has led Seattle Genetics’ capital raising interests through private and public financings by securing more than $1.2 billion. And the company’s stock price has nearly tripled over a five year period.

Siegall, who holds 15 patents, has also published more than 70 scientific pieces of writing. He has been recognized for his scientific contributions with many awards including The University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences as well as the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year.

What’s more he is a board member of Mirna Therapeutics, Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable.

Siegall graduated with a B.S. degree from the University of Maryland and went on to receive a Ph.D. from George Washington University. He started on his career as a senior research investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute.